These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24287765)

  • 21. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The path to approval of new drugs for diabetes.
    Rendell M
    Expert Opin Drug Saf; 2013 Mar; 12(2):195-207. PubMed ID: 23394462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A community-based approach to new antibiotic discovery.
    Cooper MA
    Nat Rev Drug Discov; 2015 Sep; 14(9):587-8. PubMed ID: 26265313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letter from the editor.
    Ellis R; Riedmann EM
    Hum Vaccin Immunother; 2013 Apr; 9(4):721. PubMed ID: 24091588
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug discovery and the use of computational approaches for infectious diseases.
    Marhöfer RJ; Oellien F; Selzer PM
    Future Med Chem; 2011 Jun; 3(8):1011-25. PubMed ID: 21707402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel targets for the treatment of heart failure: perspectives from a heart failure clinician and trialist.
    Massie BM
    J Mol Cell Cardiol; 2011 Oct; 51(4):438-40. PubMed ID: 21549124
    [No Abstract]   [Full Text] [Related]  

  • 27. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 28. Current world literature.
    Curr Opin Infect Dis; 2012 Dec; 25(6):718-28. PubMed ID: 23147811
    [No Abstract]   [Full Text] [Related]  

  • 29. Expediting the availability of drugs for US patients with cancer.
    Farrell AT; Pazdur R; von Eschenbach AC
    Nat Clin Pract Urol; 2008 Dec; 5(12):654-6. PubMed ID: 19050708
    [No Abstract]   [Full Text] [Related]  

  • 30. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug-device trials for infectious diseases: CDRH perspective.
    Meier KL; Gitterman S
    Clin Infect Dis; 2011 May; 52 Suppl 4():S367-72. PubMed ID: 21460298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analyzing global trends of biomarker use in drug interventional clinical studies.
    Hayashi K; Masuda S; Kimura H
    Drug Discov Ther; 2012 Apr; 6(2):102-7. PubMed ID: 22622020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A voyage of discovery.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug pipeline: Q312.
    DeFrancesco L
    Nat Biotechnol; 2012 Dec; 30(12):1164. PubMed ID: 23222776
    [No Abstract]   [Full Text] [Related]  

  • 38. The most important news at ASCO 2009.
    DeVita VT
    Nat Rev Clin Oncol; 2009 Jul; 6(7):371. PubMed ID: 19561629
    [No Abstract]   [Full Text] [Related]  

  • 39. Antimicrobial agents: the new theriac?
    Labro MT
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1363-5. PubMed ID: 23253312
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
    Peck CC; Rubin DB; Sheiner LB
    Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.